JP2008516974A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516974A5
JP2008516974A5 JP2007536972A JP2007536972A JP2008516974A5 JP 2008516974 A5 JP2008516974 A5 JP 2008516974A5 JP 2007536972 A JP2007536972 A JP 2007536972A JP 2007536972 A JP2007536972 A JP 2007536972A JP 2008516974 A5 JP2008516974 A5 JP 2008516974A5
Authority
JP
Japan
Prior art keywords
methoxy
phenyl
pyrimidin
ethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007536972A
Other languages
English (en)
Japanese (ja)
Other versions
JP4970274B2 (ja
JP2008516974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037148 external-priority patent/WO2006044732A2/en
Publication of JP2008516974A publication Critical patent/JP2008516974A/ja
Publication of JP2008516974A5 publication Critical patent/JP2008516974A5/ja
Application granted granted Critical
Publication of JP4970274B2 publication Critical patent/JP4970274B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007536972A 2004-10-15 2005-10-14 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン Expired - Fee Related JP4970274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61927204P 2004-10-15 2004-10-15
US60/619,272 2004-10-15
PCT/US2005/037148 WO2006044732A2 (en) 2004-10-15 2005-10-14 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2008516974A JP2008516974A (ja) 2008-05-22
JP2008516974A5 true JP2008516974A5 (enExample) 2008-07-31
JP4970274B2 JP4970274B2 (ja) 2012-07-04

Family

ID=36072155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536972A Expired - Fee Related JP4970274B2 (ja) 2004-10-15 2005-10-14 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン

Country Status (35)

Country Link
US (2) US8193183B2 (enExample)
EP (1) EP1891019B1 (enExample)
JP (1) JP4970274B2 (enExample)
KR (1) KR101280268B1 (enExample)
CN (1) CN101039920B (enExample)
AR (1) AR053770A1 (enExample)
AU (1) AU2005295502B2 (enExample)
BR (1) BRPI0516482A (enExample)
CA (1) CA2583742C (enExample)
CR (1) CR9003A (enExample)
DK (1) DK1891019T3 (enExample)
EC (1) ECSP077398A (enExample)
ES (1) ES2392091T3 (enExample)
GT (1) GT200500284A (enExample)
HN (1) HN2005000795A (enExample)
IL (1) IL182090A (enExample)
MA (1) MA29071B1 (enExample)
MX (1) MX2007003155A (enExample)
MY (2) MY157036A (enExample)
NO (1) NO339772B1 (enExample)
NZ (1) NZ553919A (enExample)
PA (1) PA8649801A1 (enExample)
PE (1) PE20060936A1 (enExample)
PL (1) PL1891019T3 (enExample)
PT (1) PT1891019E (enExample)
RU (1) RU2417990C2 (enExample)
SG (1) SG156653A1 (enExample)
SI (1) SI1891019T1 (enExample)
SV (1) SV2006002272A (enExample)
TN (1) TNSN07098A1 (enExample)
TW (1) TWI372751B (enExample)
UA (1) UA88485C2 (enExample)
UY (1) UY29167A1 (enExample)
WO (1) WO2006044732A2 (enExample)
ZA (1) ZA200702209B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5427769B2 (ja) * 2007-03-30 2014-02-26 サノフイ Pgds阻害剤としてのピリミジンヒドラジド化合物
NZ580660A (en) * 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
JP2010532366A (ja) 2007-06-29 2010-10-07 サノフィ−アベンティス 2−(3−{6−[2−(2,4−ジクロロフェニル)−エチルアミノ]−2−メトキシピリミジン−4−イル}−フェニル)−2−メチルプロピオン酸を製造する新しい方法
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Pi3キナーゼ調節剤および使用方法
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
EP2205086B1 (en) * 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
WO2011115943A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
KR20130018770A (ko) * 2010-03-16 2013-02-25 아벤티스 파마슈티칼스 인크. 프로스타글란딘 d2 수용체 길항제들로서의 치환된 피리미딘들
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8575158B2 (en) 2010-07-05 2013-11-05 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
RU2626956C2 (ru) * 2011-06-06 2017-08-02 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
BR112014015081A8 (pt) 2011-12-21 2017-06-13 Actelion Pharmaceuticals Ltd derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 1−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
JP6360878B2 (ja) 2013-03-12 2018-07-18 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
JP2018123058A (ja) * 2015-06-08 2018-08-09 石原産業株式会社 ジフルオロメチレン化合物
CN106336374A (zh) * 2015-07-06 2017-01-18 江苏恩华药业股份有限公司 阿芬太尼、舒芬太尼的制备方法及用于制备阿芬太尼、舒芬太尼的化合物
EP3323817B1 (en) * 2015-07-16 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Aniline pyrimidine derivatives and uses thereof
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
EP3551611A1 (en) * 2016-12-09 2019-10-16 Celtaxsys Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
CN110621671A (zh) * 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド N-置換インドール誘導体
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
US20220064146A1 (en) * 2018-12-31 2022-03-03 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN110642880B (zh) * 2019-10-11 2021-12-31 长沙麓兴生物科技有限公司 一种氮未取代吡唑和吲唑类硼酸的制备方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
WO2022038170A1 (en) * 2020-08-18 2022-02-24 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
CN116507611A (zh) * 2020-11-06 2023-07-28 佩勒梅德有限公司 新型衣壳组装抑制剂
CN117599052A (zh) * 2023-07-25 2024-02-27 温州医科大学附属眼视光医院 Ptgds的抑制剂在制备治疗白内障药物上的应用
US12220411B1 (en) 2023-07-25 2025-02-11 The Eye Hospital Of Wenzhou Medical University Application of PTGDS inhibitor in preparation of drug for treating cataracts
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH478819A (de) * 1965-10-22 1969-09-30 Ciba Geigy Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
GB1143167A (en) * 1967-01-25 1969-02-19 Ucb Sa Derivatives of pyrimidine
DE4031798A1 (de) * 1990-10-08 1992-04-09 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4031792A1 (de) * 1990-10-08 1991-04-25 Franz Reiner Dipl Phy Thedieck Indikator-element aus festen bestandteilen
FR2753378B1 (fr) * 1996-09-17 1998-11-20 Oreal Utilisation dans une composition en tant que stimulateur de tyrosinase d'au moins un derive de pyrimidine 3-oxyde, substitue en 6
US6169086B1 (en) * 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
JP2003505384A (ja) * 1999-07-15 2003-02-12 ファーマコピーア,インコーポレーティッド ブラジキニンb1受容体アンタゴニスト
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE60217669D1 (de) * 2001-05-14 2007-03-08 Bristol Myers Squibb Co Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
AU2002310187A1 (en) * 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
US7176312B2 (en) * 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US20070155701A1 (en) 2002-08-23 2007-07-05 Alexandros Makriyannis Keto cannabinoids with therapeutic indications
JP2005536554A (ja) 2002-08-23 2005-12-02 ユニバーシティ オブ コネチカット 新規なビフェニル及びビフェニル様カンナビノイド
CA2496097A1 (en) * 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
HRP20050529A2 (en) * 2002-11-11 2006-08-31 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
BRPI0412915A (pt) * 2003-07-25 2006-09-26 Ciba Sc Holding Ag uso de 2,4-bis(alquilamino)pirimidinas ou -quinazolinas substituìdas como antimicrobianos
MXPA06010900A (es) * 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
DE602005027825D1 (de) * 2004-03-30 2011-06-16 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
EP1805142A4 (en) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
CN101098872B (zh) * 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

Similar Documents

Publication Publication Date Title
JP2008516974A5 (enExample)
CA2583742A1 (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
CN101492416B (zh) 影响葡糖激酶的化合物
US7211594B2 (en) Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
RU2012116207A (ru) Производные индола в качестве модуляторов crac
CA2483159A1 (en) Triazole derivatives as tachykinin receptor antagonists
US9580438B2 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
AU2004266719A1 (en) Methods of treating COPD and pulmonary hypertension
JP2016522246A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2005536458A5 (enExample)
JP2009533427A5 (enExample)
JP2018534328A5 (enExample)
RU2003118448A (ru) Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы
JP2007530690A5 (enExample)
JP2017537948A5 (enExample)
JP2010504280A5 (enExample)
JP2008500336A5 (enExample)
JP2016523976A5 (enExample)
JP2014523400A5 (enExample)
JP2009541268A5 (enExample)
BRPI0720270A2 (pt) Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos
JP2020520354A5 (enExample)
US20070185163A1 (en) Imidazol derivatives of piperidine as histamine antagonists
HRP20160359T1 (hr) Derivati kinazolindiona, njihovo dobivanje i njihove terapijske primjene